Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Clinical trial NCT03552471 · COMPLETED

Trial details

NCT number: NCT03552471
Sponsor: Ohio State University Comprehensive Cancer Center
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

BRCA1 Gene Mutation BRCA2 Gene Mutation Folate Receptor Alpha Positive Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Recurrent Uterine Corpus Carcinoma Recurrent Uterine Serous Carcinoma Recurrent Uterine Carcinosarcoma Platinum Resistant Ovarian Cancer

Start date: 2018-07-12
Primary completion: 2022-06-24
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.